This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Names | |
---|---|
Preferred IUPAC name
1-(2H-1,3-Benzodioxol-5-yl)-N-ethylbutan-2-amine | |
Other names
3,4-Methenedioxy-α,N-diethyl-phenethylamine; 3,4-Methylenedioxy-N-ethylbutanphenamine; MDEB
| |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C13H19NO2 | |
Molar mass | 221.300 g·mol−1 |
Melting point | 176 to 177 °C (349 to 351 °F; 449 to 450 K) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Ethylbenzodioxolylbutanamine (EBDB; Ethyl-J) is a lesser-known entactogen, stimulant, and psychedelic of the phenethylamine, amphetamine, and phenylisobutylamine families. It is the N-ethyl analogue of benzodioxylbutanamine (BDB; "J"), and also the α-ethyl analogue of methylenedioxyethylamphetamine (MDEA; "Eve").
EBDB was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage consumed was 90 mg, and the duration is unknown.[1] EBDB produced few to no effects at the dosage range tested in PiHKAL, but at higher doses of several hundred milligrams it produces euphoric effects similar to those of methylbenzodioxylbutanamine (MBDB; "Eden", "Methyl-J"), although milder and shorter lasting.[citation needed]
Very little data exists about the pharmacological properties, metabolism, and toxicity of EBDB.